Form 4: Amicus Therapeutics CEO Bradley Campbell Executes Stock Option and Sells Shares
SEC Form 4 Filing
Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 1, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 7,500 shares of common stock at a price of $8.61 per share.
- Simultaneously, Campbell sold 7,500 shares of common stock at a weighted average price of $10.3358, with prices ranging from $10.26 to $10.39.
- Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock.
- The transactions were executed under a Rule 10b5-1 trading plan adopted on August 23, 2023.
- Campbell continues to hold 30,000 stock options.
Sentiment
Score: 6
Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, mitigating potential negative interpretations. However, any insider selling can create slight uncertainty.
Positives
- The CEO's transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Negatives
- The CEO sold shares, which could be interpreted negatively by some investors, although it was part of a pre-planned strategy.
Risks
- Executive stock sales can sometimes create uncertainty among investors, even when conducted under a 10b5-1 plan.
Industry Context
Executive stock transactions are common and closely monitored in the pharmaceutical industry. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about trading on non-public information.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units.
- Companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical also see regular Form 4 filings related to executive stock transactions.
- The use of Rule 10b5-1 trading plans is a standard practice among publicly traded companies to manage insider trading risks.
Stakeholder Impact
- The transactions could have a minor impact on shareholder sentiment, depending on how they are perceived.
Key Dates
| Date | Description |
|---|---|
| 2023-08-23 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-08-01 | Date of stock option exercise and stock sale. |
| 2025-01-02 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.